Patents by Inventor Andrew Alistair WYLIE

Andrew Alistair WYLIE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
    Patent number: 11787813
    Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5?, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: October 11, 2022
    Date of Patent: October 17, 2023
    Assignee: KSQ Therapeutics, Inc.
    Inventors: Jehrod Burnett Brenneman, Elsa Beyer Krall, Michael Schlabach, Andrew Alistair Wylie
  • THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
    Publication number: 20230277533
    Abstract: The present disclosure provides therapeutic combinations comprising (i) a ubiquitin-specific-processing protease 1 (USP1) inhibitor and (ii) a poly ADP-ribose polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof, wherein the USP1 inhibitor comprises (I), (II), or (III), or pharmaceutically acceptable salts, hydrates, solvates, amorphous solids, or polymorphs thereof. The present disclosure is also directed to the use of the combinations to inhibit a USP1 and/or PARP protein and/or to treat a disorder responsive to the inhibition of USP1 and/or PARP proteins and USP1 and/or PARP activity. The combinations of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: February 12, 2021
    Publication date: September 7, 2023
    Inventors: Andrew Alistair WYLIE, Solomon Martin SHENKER, Pamela Jean SULLIVAN, Frank STEGMEIER, Anne Louise CADZOW, Hanlan LIU, Kerstin Wolf SINKEVICIUS
  • SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS
    Publication number: 20230203046
    Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5?, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: October 11, 2022
    Publication date: June 29, 2023
    Inventors: Jehrod Burnett BRENNEMAN, Elsa Beyer KRALL, Michael SCHLABACH, Andrew Alistair WYLIE
  • Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
    Patent number: 11485736
    Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5?, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: November 1, 2022
    Assignee: KSQ Therapeutics, Inc.
    Inventors: Jehrod Burnett Brenneman, Elsa Beyer Krall, Michael Schlabach, Andrew Alistair Wylie
  • SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS
    Publication number: 20210115049
    Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5?, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 22, 2021
    Inventors: Jehrod Burnett BRENNEMAN, Elsa Beyer KRALL, Michael SCHLABACH, Andrew Alistair WYLIE